Hadassah

Placental Cells Found to Have Potential to Mitigate Acute Radiation Syndrome

Monday, Oct 24 2011

"In pre-clinical studies," notes Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory at the Sharrett Institute of Oncology at Hadassah University Medical Center, "we found that placental-derived cells potentially have the ability to increase the survival rate of animals following exposure to lethal doses of total body irradiation."

These placental (PLX) cells, developed by Pluristem Therapeutics Inc., treat life-threatening complications associated with Acute Radiation Syndrome (ARS).

During the studies, animals were injected intravenously with either PLX cells or a placebo, on the day after being exposed to lethal doses of radiation. Nine days following treatment with the PLX cells, the animals' bone marrow and spleen were examined for signs of hematopoietic (blood forming) tissue. On day 23, bone marrow and blood samples were examined in the surviving animals. Overall survival and body weight changes were also monitored. The researchers found in the animals treated with the PLX cells:

  • an up to four-fold increase in the survival rate accompanied by a corresponding weight regain
  • an increase in red-cell count on days 21-23
  • an elevated number of hematopoietic colonies on day 9

Over the next few months, Prof. Gorodetsky and his team will focus on better understanding the PLX cells' mechanism of action as an "off the shelf" post radiation treatment, which could potentially be used in the future for treating ARS patients.

"While our experiments using PLX cells in treating radiation exposure are ongoing and still evolving, these initial data are very encouraging," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "PLX cells as a sole treatment may potentially enhance the survival of lethally irradiated individuals. Moreover, since our previous work indicated that PLX cells can enhance the engraftment of hematopoietic stem cells from cord blood, we can offer a multifaceted approach to reduce and treat the destruction of bone marrow that occurs following exposure to high-dose ionizing radiation. Stockpiled PLX cells can be administered acutely and as a bridging therapy to protect the bone marrow."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Dec 15 2017

The Pediatric Intensive Care Unit (PICU) at Hadassah Hospital

An intimate video tour of the Pediatric Intensive Care Unit (PICU) at Hadassah Hospital highlights the miraculous recoveries of children given a second chance, with firsthand accounts from their grateful parents and their extraordinary doctors and nurses.

READ MORE ›
alt_text

Tuesday, Dec 12 2017

Hadassah Mount Scopus Rehab Gets Boost at Hadassah International Israel Gala Dinner

More than a thousand Israelis expressed their support for the eagerly anticipated new Hadassah Hospital Mount Scopus rehabilitation center for wounded soldiers and terror survivors at a gala event sponsored by Hadassah International Israel at the David International Hotel in Tel Aviv.

READ MORE ›
alt_text

Tuesday, Dec 12 2017

Older People Who Get Out Live Longer

A study led by Hadassah Physician Dr. Jeremy Michael Jacobs, Chair of the Hadassah Medical Organization’s Geriatric and Rehabilitation Complex, reveals that individuals between the ages of 70 and 90 who leave the house daily have a lower risk of mortality, independent of social, functional or medical status.

READ MORE ›
alt_text

Monday, Dec 11 2017

Twin boy Saved by Hadassah Experts and Cutting-Edge Technology

Simcha and his twin sister, Sarah, were born to a Jerusalem couple in their early forties, after years of hoping for children.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More